EGFR and non-small cell lung carcinoma: We retrospectively analyzed data on a total of 167 samples from advanced stage NSCLC PD-L1 positive patients (≥1%) who were referred to our clinic for molecular evaluation of at least five proto-oncogenes, namely, EGFR, KRAS, BRAF, ALK and ROS1.